Compare Novartis with SEASONS FUR. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SEASONS FUR. - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SEASONS FUR. NOVARTIS/
SEASONS FUR.
 
P/E (TTM) x 84.6 9.5 886.1% View Chart
P/BV x 2.6 - - View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 NOVARTIS   SEASONS FUR.
EQUITY SHARE DATA
    NOVARTIS
Mar-21
SEASONS FUR.
Mar-21
NOVARTIS/
SEASONS FUR.
5-Yr Chart
Click to enlarge
High Rs7703 26,369.9%   
Low Rs5011 52,736.8%   
Sales per share (Unadj.) Rs154.54.8 3,250.1%  
Earnings per share (Unadj.) Rs8.5-3.6 -235.4%  
Cash flow per share (Unadj.) Rs13.4-3.4 -388.7%  
Dividends per share (Unadj.) Rs10.000-  
Avg Dividend yield %1.60-  
Book value per share (Unadj.) Rs289.2-1.4 -20,337.8%  
Shares outstanding (eoy) m24.697.39 334.1%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x4.10.4 1,009.9%   
Avg P/E ratio x75.1-0.5 -13,948.8%  
P/CF ratio (eoy) x47.5-0.6 -8,446.7%  
Price / Book Value ratio x2.2-1.4 -161.4%  
Dividend payout %118.10-   
Avg Mkt Cap Rs m15,69114 109,669.8%   
No. of employees `000NANA-   
Total wages/salary Rs m1,0851 80,377.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,81435 10,858.5%  
Other income Rs m3320-   
Total revenues Rs m4,14635 11,803.8%   
Gross profit Rs m267-24 -1,116.3%  
Depreciation Rs m1221 10,857.1%   
Interest Rs m772 4,923.1%   
Profit before tax Rs m400-27 -1,506.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1910-   
Profit after tax Rs m209-27 -786.3%  
Gross profit margin %7.0-68.1 -10.3%  
Effective tax rate %47.80 -977,371.1%   
Net profit margin %5.5-75.7 -7.2%  
BALANCE SHEET DATA
Current assets Rs m9,224135 6,840.8%   
Current liabilities Rs m3,57372 4,959.9%   
Net working cap to sales %148.2178.8 82.9%  
Current ratio x2.61.9 137.9%  
Inventory Days Days17620 890.3%  
Debtors Days Days37778,189,083 0.0%  
Net fixed assets Rs m2,48013 19,403.8%   
Share capital Rs m12374 166.9%   
"Free" reserves Rs m7,018-84 -8,310.2%   
Net worth Rs m7,141-11 -67,948.6%   
Long term debt Rs m086 0.0%   
Total assets Rs m11,703148 7,928.5%  
Interest coverage x6.2-16.0 -38.7%   
Debt to equity ratio x0-8.2 0.0%  
Sales to assets ratio x0.30.2 137.0%   
Return on assets %2.4-16.9 -14.4%  
Return on equity %2.9252.9 1.2%  
Return on capital %6.7-33.1 -20.2%  
Exports to sales %9.30-   
Imports to sales %04.2 0.0%   
Exports (fob) Rs m354NA-   
Imports (cif) Rs mNA1 0.0%   
Fx inflow Rs m3540-   
Fx outflow Rs m9741 66,276.2%   
Net fx Rs m-621-1 42,223.8%   
CASH FLOW
From Operations Rs m-6923 -23,865.5%  
From Investments Rs m952NA -4,758,000.0%  
From Financial Activity Rs m-368-3 14,545.5%  
Net Cashflow Rs m-1090 -31,000.0%  

Share Holding

Indian Promoters % 0.0 65.9 -  
Foreign collaborators % 70.7 0.0 -  
Indian inst/Mut Fund % 0.8 0.0 8,100.0%  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 29.3 34.2 85.9%  
Shareholders   45,141 3,344 1,349.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   HCL INFOSYS    MMTC    SUNDRAM FASTENERS    FUTURE CONSUMER    STC INDIA    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 21, 2022 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS